A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

By Geeta A. Lalwani, P. Rosenfeld, A. Fung, Sander R. Dubovy, S. Michels, W. Feuer, Janet L. Davis, H. Flynn, Maria Esquiabro. American journal of ophthalmology-glaucoma, 2009

960 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/c1ae14fabb17555a1fd4e7d665e0f3c33cf3328f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis
2. N. Ferrara

In Ophthalmology

1. David M. Brown
2. N. Ferrara
3. A. Adamis

Citations in the corpus

• Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, positive): “Pro re nata (PRN) treatment, or treatment as needed, was evaluated first in the Prospective Optical Coherence Tomography Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PRONTO) study, a small, single-center, carefully monitored investigatordriven trial.(9) Physicians ”